Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Keyphrases

• Randomized Double-blind 100%
• Glioblastoma 100%
• Temozolomide 100%
• Newly Diagnosed 100%
• Phase II Trial 100%
• EGFRvIII 100%
• Rindopepimut 100%
• Adverse Events 18%
• Overall Survival 18%
• Seizure 18%
• Newly Diagnosed Glioblastoma 18%
• Chemoradiation 18%
• Keyhole Limpet Hemocyanin 18%
• Brain Edema 18%
• No Significant Difference 9%
• Headache 9%
• Median Overall Survival 9%
• Granulocyte Colony-stimulating Factor (G-CSF) 9%
• Pulmonary Embolism 9%
• Cancer Treatment 9%
• Serious Adverse Events 9%
• Conventional Chemotherapy 9%
• Interim Analysis 9%
• Specific Peptide 9%
• Thrombocytopenia 9%
• Surgical Resection 9%
• Young Males 9%
• Male Patients 9%
• Vaccine Target 9%
• Minimal Residual Disease 9%
• Residual Disease 9%
• Intolerance 9%
• Recursive Partitioning Analysis 9%
• Treatment Allocation 9%
• Combined Method 9%
• Intradermal Injection 9%
• Central Review 9%
• European Organizations 9%
• Block Size 9%
• Deletion mutation 9%
• MGMT Promoter Methylation 9%
• Modified Intention-to-treat 9%
• Enhancing Tumor 9%
• CDX-110 9%

Medicine and Dentistry

• Glioblastoma 100%
• Temozolomide 100%
• Rindopepimut 100%
• Adverse Event 27%
• Overall Survival 27%
• Epileptic Seizure 18%
• Chemoradiotherapy 18%
• Brain Edema 18%
• Minimal Residual Disease 18%
• Keyhole Limpet Hemocyanin 18%
• Headache 9%
• Immunotherapy 9%
• Promoter Region 9%
• Pulmonary Embolism 9%
• Cancer Treatment 9%
• Tumor 9%
• Intention-to-Treat Analysis 9%
• Epidermal Growth Factor Receptor 9%
• Thrombocytopenia 9%
• Methylation 9%
• Recursive Partitioning 9%
• Granulocyte Macrophage Colony Stimulating Factor 9%
• Interim Analysis 9%
• Intradermal Drug Administration 9%
• Oral 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Temozolomide 100%
• Glioblastoma 100%
• Rindopepimut 100%
• Adverse Event 27%
• Overall Survival 27%
• Chemoradiation Therapy 18%
• Brain Edema 18%
• Minimal Residual Disease 18%
• Keyhole Limpet Hemocyanin 18%
• Malignant Neoplasm 9%
• Headache 9%
• Chemotherapy 9%
• Epidermal Growth Factor Receptor 9%
• Granulocyte Macrophage Colony Stimulating Factor 9%
• Immunotherapy 9%
• Thrombocytopenia 9%
• Lung Embolism 9%